Is Ono Pharmaceutical (TSE:4528) Quietly Recasting Its Pipeline Strategy With These New Partnerships?

In early March 2026, Ono Pharmaceutical expanded its drug discovery collaborations with Congruence Therapeutics in neurology and immunology and partnered with Sinopia Biosciences on rare metabolic disorders, while also moving to transfer its Japanese Forxiga distribution back to AstraZeneca and introducing a long-term incentive stock plan for Deciphera employees.
Together, these moves highlight Ono’s push to diversify its pipeline into areas of significant unmet medical need while refining...